Revolution Medicines, Inc. (RVMD) Financial Statements

Executive TeamFinancials
Shareholders

Revolution Medicines financial statements at a glance

Revolution Medicines reported revenue of $0 for fiscal year 2025 (ended December 31, 2025). Net income was -$1.13 billion, and diluted earnings per share were -$5.95.

At the end of fiscal year 2025 it had total assets of $2.35 billion, total liabilities of $723.21 million and shareholders' equity of $1.63 billion, with cash and short-term investments of $2.03 billion and total debt of $158.70 million.

Its operations brought in -$897.74 million of cash; capital spending was $15.99 million, leaving free cash flow of -$913.73 million.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

RVMD logo

Revolution Medicines, Inc.

RVMDUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
0
Prev Year: 0
Total Expenses
1.18B
Prev Year: 689.52M
YoY: +71.5%
Total Operating Income as Reported
-1.18B
Prev Year: -689.52M
YoY: -71.5%
Diluted NI Available to Com Stockholders
-1.13B
Prev Year: -600.09M
YoY: -88.5%
Gain on Sale of Securities
-15.36M
Prev Year: 4.32M
YoY: -455.3%
Operating Expense
1.18B
Prev Year: 689.52M
YoY: +71.5%
Selling General and Administrative
195.04M
Prev Year: 97.30M
YoY: +100.5%
General and Administrative Expense
195.04M
Prev Year: 97.30M
YoY: +100.5%
Other General and Administrative
195.04M
Prev Year: 97.30M
YoY: +100.5%
Research and Development
987.33M
Prev Year: 592.23M
YoY: +66.7%
Operating Income
-1.18B
Prev Year: -689.52M
YoY: -71.5%
Net Non Operating Interest Income Expense
66.46M
Prev Year: 86.88M
YoY: -23.5%
Non-operating Interest Income
90.69M
Prev Year: 86.88M
YoY: +4.4%
Non-operating Interest Expense
24.23M
Other Income Expense
-15.39M
Prev Year: 1.79M
YoY: -957.7%
Other Non-operating Income (expense)
-37.0K
Prev Year: -2.53M
YoY: +98.5%
Pre-tax Income
-1.13B
Prev Year: -600.85M
YoY: -88.3%
Net Income Common Stockholders
-1.13B
Prev Year: -600.09M
YoY: -88.5%
Net Income
-1.13B
Prev Year: -600.09M
YoY: -88.5%
Net Income Including Non-Controlling Interests
-1.13B
Prev Year: -600.09M
YoY: -88.5%
Net Income from Continuing Operations
-1.13B
Prev Year: -600.09M
YoY: -88.5%
Basic EPS
-5.95
Prev Year: -3.58
YoY: -66.2%
Diluted EPS
-5.95
Prev Year: -3.58
YoY: -66.2%
Weighted Average Shares (basic)
190.13M
Prev Year: 167.74M
YoY: +13.3%
Weighted Average Shares (diluted)
190.13M
Prev Year: 167.74M
YoY: +13.3%
Net Income from Continuing and Discontinued Operation
-1.13B
Prev Year: -600.09M
YoY: -88.5%
Normalized Income
-1.12B
Prev Year: -604.41M
YoY: -84.6%
Interest Income
90.69M
Prev Year: 86.88M
YoY: +4.4%
Interest Expense
24.23M
Net Interest Income
66.46M
Prev Year: 86.88M
YoY: -23.5%
EBIT
-1.11B
Prev Year: -689.52M
YoY: -60.6%
EBITDA
-1.09B
Prev Year: -677.70M
YoY: -60.9%
Reconciled Depreciation
16.56M
Prev Year: 11.82M
YoY: +40.0%
Net Income from Continuing Operation Net Minority Interest
-1.13B
Prev Year: -600.09M
YoY: -88.5%
Normalized EBITDA
-1.08B
Prev Year: -682.02M
YoY: -57.6%
Total Unusual Items
-15.36M
Prev Year: 4.32M
YoY: -455.3%
Total Unusual Items Excluding Goodwill
-15.36M
Prev Year: 4.32M
YoY: -455.3%
Values in USD

Revolution Medicines key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$0$0$11.6M$35.4M$29.4M
Operating income-$1.2B-$689.5M-$487.2M-$258.3M-$188.0M
Net income-$1.1B-$600.1M-$436.4M-$248.7M-$187.1M
Diluted EPS-$5.95-$3.58-$3.86-$3.08-$2.57
Total assets$2.4B$2.6B$2.1B$811.9M$738.0M
Total liabilities$723.2M$293.1M$235.5M$126.7M$135.4M
Shareholders' equity$1.6B$2.3B$1.8B$685.2M$602.6M
Cash and short-term investments$2.0B$2.3B$1.9B$644.9M$577.1M
Total debt$158.7M$135.8M$87.9M$64.2M$66.6M
Operating cash flow-$897.7M-$557.4M-$350.6M-$224.4M-$147.2M
Capital spending$16.0M$10.3M$7.7M$10.8M$6.5M
Free cash flow-$913.7M-$567.7M-$358.3M-$235.2M-$153.7M

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2017.

Questions and answers

What was Revolution Medicines's revenue in fiscal year 2025?

$0.

How much profit does Revolution Medicines make?

Revolution Medicines reported net income of -$1.13 billion for fiscal year 2025; operating income was -$1.18 billion.

How much cash and debt does Revolution Medicines have?

At the end of fiscal year 2025: cash and short-term investments of $2.03 billion and total debt of $158.70 million.

What is Revolution Medicines's free cash flow?

-$913.73 million in fiscal year 2025 (operating cash flow of -$897.74 million minus capital spending of $15.99 million).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube